Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration

Next Previous
Trial Profile

A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Qilu Pharmaceutical

Most Recent Events

  • 19 Dec 2022 This trial has been completed in Bulgaria (End Date: 10 June 2022), according to European Clinical Trials Database record.
  • 09 Dec 2022 This trial has been completed in Poland (End Date: 10 June 2022), according to European Clinical Trials Database record
  • 10 Sep 2022 This trial has been completed in Slovakia (End Date: 10 June 2022), according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top